MXC’s Derma division receives first purchase order with $8M deal
Published 15-NOV-2017 10:58 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
European-based specialist medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), has revealed some promising news relating to its MGC Derma division, marking its first material revenues.
MGC Derma has now received its first formal purchase order from Varm Cosmo for cannabidiol (CBD) cosmetic products under an $8 million binding sales agreement. These products will be sold to consumers as part of Varm Cosmo’s cosmetics range.
This comes bang on schedule, delivering as promised in MXC’s October announcement.
MGC Derma is a joint venture with widely recognised cosmetic manufacturer, Dr. M. Burstein Ltd, of which MXC owns 51 per cent and holds management control.
Varm Cosmo is a strongly backed, emerging Korean health care and beauty cosmetics company with a global distribution network, and sells its CBD range online and through a number of retail outlets.
This alliance is a major strategic entry point for MXC into the massive global cosmetics market.
The agreement is for a minimum contracted volume of $8 million of product. The MGC Derma products delivered will be marketed and sold by Varm Cosmo under a new premium brand, which will be launched in coming months.
Significantly, this initial purchase order wll deliver the first material revenues for MGC Derma within days, and forms part of the $1 million deposit, which is on track to be received in November.
However, those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.
Under the terms of the agreement, this first payment is to be paid to MGC Derma within five business days of the purchase order.
MXC is now in advanced stages of negotiation with Varm Cosmo for the two additional contracts, which will deliver MGC Derma products into new Varm Cosmo markets. These agreements are expected to close by both parties in the coming weeks to complete the full $40 million supply agreement.
This news puts MXC on a major high. The company is in a sound financial position, with $9.5 million cash in the bank and no debt, and is now entering its revenue phase at full throttle.
Roby Zomer, MXC co-founder and CEO, said “The receipt of the first purchase order signals a milestone for our company under what is a transformational deal that will not only deliver significant revenues but also provide a platform for MGC Derma to rapidly expand its presence in the global cosmetics market, which presents a very large opportunity for our company.”
“Furthermore, this milestone will generate additional revenue stream from our CBD extractions produced by our Pharma division.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
